List of Excipients in Branded Drug VERAPAMIL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	FD&C RED NO. 40
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	FERRIC OXIDE YELLOW
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	FUMARIC ACID
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	GELATIN
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	METHYLPARABEN
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	POVIDONE
Teva Pharmaceuticals Inc	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	0591-2880	PROPYLPARABEN

Generic Drugs Containing VERAPAMIL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	MICROCRYSTALLINE CELLULOSE 101
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	POLYETHYLENE GLYCOL 3350
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	POLYVINYL ALCOHOL
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	POVIDONE
Mylan Pharmaceuticals Inc	verapamil hydrochloride	0378-2120	SODIUM ALGINATE

What are the Most Frequently-Used Excipients in VERAPAMIL HYDROCHLORIDE?

# Of NDCs	Excipient
1	ALGIN
3	ALUMINUM OXIDE
5	AMMONIA
17	ANHYDROUS LACTOSE
11	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
5	CARNAUBA WAX
104	CELLULOSE, MICROCRYSTALLINE

Verapamil Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: July 31, 2026

Verapamil hydrochloride is a mature, genericized calcium-channel blocker with established markets in hypertension, angina, supraventricular tachycardia, and selected arrhythmias. Commercial value has shifted from active-ingredient exclusivity to formulation performance, delivery convenience, supply reliability, and regulatory differentiation. The strongest opportunities are extended-release products, sprinkle-compatible multiparticulates, pediatric or dysphagia-friendly liquids, low-risk injectable presentations, and geographic markets where branded or high-quality generic supply remains limited.

What is the regulatory and commercial status of verapamil hydrochloride?

Verapamil hydrochloride is approved in the United States in immediate-release oral tablets, extended-release tablets or capsules, and injectable dosage forms. Products are approved for cardiovascular indications that include hypertension, chronic stable angina, vasospastic angina, and rate control in supraventricular tachyarrhythmias, depending on the product label.[1-4]

Attribute	Current position
Active ingredient	Verapamil hydrochloride
Therapeutic class	Non-dihydropyridine calcium-channel blocker
Primary uses	Hypertension, angina, supraventricular tachycardia, ventricular-rate control
U.S. dosage forms	Immediate-release tablets, extended-release tablets/capsules, injection
Reference brands	Calan, Calan SR, Isoptin SR, Verelan and related historical products
Generic status	Established; multiple abbreviated new drug application products
Biologic status	Not applicable; biosimilar competition does not apply
Core commercial issue	Formulation quality, dose flexibility, release control and supply reliability
Patent environment	Originator exclusivity has expired; product-level generic competition is established

Verapamil has a narrow therapeutic margin relative to many primary-care medicines. Excess exposure can produce hypotension, bradycardia, atrioventricular block, and worsening heart failure. The excipient system therefore must support consistent potency, dissolution, release rate, and dose delivery across the product shelf life.[1-4]

What excipients are used in verapamil hydrochloride products?

The excipient profile depends on the delivery system. Immediate-release products prioritize manufacturability and rapid dissolution. Extended-release products require a release-controlling matrix, coated pellets, or another multiparticulate architecture. Injectable products require parenteral-grade excipients and tight control of pH, particulate matter, sterility, and container compatibility.

Immediate-release tablets

Immediate-release verapamil tablets generally use conventional tableting excipients such as:

• Lactose or another water-soluble diluent
• Microcrystalline cellulose
• Pregelatinized starch or maize starch
• Povidone or another binder
• Crospovidone, croscarmellose sodium, or sodium starch glycolate
• Colloidal silicon dioxide
• Magnesium stearate or another lubricant
• Film-coating polymers, plasticizers, pigments, and opacifiers

The optimal system depends on the target tablet strength. Verapamil hydrochloride is a potent, relatively low-dose active ingredient compared with the total tablet mass, so blend uniformity and segregation control are important. A direct-compression formula may reduce processing steps, but a wet-granulation process can improve content uniformity and flow where the drug load is low or the powder blend is cohesive.

Excipient selection should account for:

1. Powder segregation during transfer and compression.
2. Content uniformity at low drug loading.
3. Rapid disintegration without excessive tablet friability.
4. Consistent dissolution across multiple strengths.
5. Moisture protection during storage.

Extended-release matrix tablets

Hydrophilic matrix systems commonly use hypromellose, also known as hydroxypropyl methylcellulose, to control water penetration and drug diffusion. Other formulation options include polyethylene oxide, carbomer, ethylcellulose, methacrylate copolymers, or combinations of hydrophilic and hydrophobic polymers.

A matrix product can be designed around:

• High-viscosity hypromellose for stronger gel formation
• Low-viscosity hypromellose for faster hydration and release
• Ethylcellulose or waxes for diffusion control
• Polyethylene oxide for robust gel strength
• Colloidal silicon dioxide to improve flow
• Compression aids to maintain tablet integrity
• Film coating to control moisture and appearance

Verapamil extended-release performance is sensitive to polymer grade, particle size, polymer concentration, tablet hardness, compression force, and dissolution media. A formulation that meets a single dissolution specification may still be vulnerable to dose dumping, food effects, alcohol effects, or scale-up variability if the polymer network is not well characterized.

Multiparticulate extended-release capsules

Multiparticulate systems use drug-loaded pellets or beads enclosed in a capsule. The pellets can be coated with polymers that control diffusion, including ethylcellulose and ammonio methacrylate copolymers. A typical architecture may include:

1. Inert sugar or microcrystalline cellulose starter cores.
2. Drug-layering suspension or solution containing verapamil hydrochloride and a binder.
3. Seal coat or subcoat.
4. Rate-controlling polymer membrane.
5. Optional pore former or protective overcoat.
6. Capsule filling with a defined pellet weight.

Multiparticulates provide several commercial advantages. They can reduce local concentration spikes in the gastrointestinal tract, support more consistent release, and create sprinkle-compatible products for patients who cannot swallow intact capsules. The product label must define whether the capsule may be opened and whether the pellets may be sprinkled on soft food. Pellets must not be crushed or chewed if that action compromises release control.[3]

Injectable products

Verapamil hydrochloride injection contains a sterile aqueous solution with formulation controls directed at solubility, stability, sterility, and vascular tolerability. Common excipient categories include:

• Water for injection
• pH-adjusting agents
• Sodium chloride or another tonicity modifier
• Nitrogen or other headspace-control measures where applicable
• Container and closure components qualified for parenteral use

The injectable formulation must control pH, particulate matter, extractables and leachables, visible and subvisible particles, and interaction with glass or polymer containers. The FDA label warns that intravenous verapamil requires appropriate monitoring because of clinically significant effects on conduction, blood pressure, and cardiac function.[4]

How should an excipient strategy differ by dosage form?

Dosage form	Primary excipient objective	Key development risk	Commercial opportunity
Immediate-release tablet	Blend uniformity and fast disintegration	Segregation, friability, variable dissolution	Low-cost, high-volume generic supply
Extended-release matrix tablet	Reproducible release over the dosing interval	Polymer variability, food effect, dose dumping	Once- or twice-daily differentiation
Multiparticulate capsule	Controlled release with dose flexibility	Coating uniformity and capsule fill variation	Sprinkle use, swallowing convenience
Oral solution or suspension	Accurate dose delivery and chemical stability	Solubility, taste, precipitation, microbial control	Pediatric, geriatric and dysphagia markets
Injection	Sterility, stability and safe administration	Particles, container interaction, pH drift	Hospital supply and shortage mitigation

The formulation target should be defined before excipient screening. A company seeking an ANDA for a conventional tablet should prioritize bioequivalence, dissolution matching, and manufacturing cost. A company pursuing a differentiated product can justify more complex excipient systems if the product provides meaningful dosing or administration benefits.

What excipient opportunities exist for extended-release verapamil?

Extended-release verapamil offers the most technically defensible formulation opportunity because release performance is central to clinical use and generic substitution.

Polymer platform optimization

A development program can evaluate hypromellose grades by viscosity, substitution type, particle size, and hydration behavior. Combining hydrophilic and hydrophobic polymers may reduce sensitivity to agitation and media changes. The commercial objective is not simply slower dissolution. It is a reproducible release profile that remains within specification across:

• Different tablet hardness levels
• Commercial-scale compression speeds
• Storage humidity
• Fed and fasted conditions
• Relevant pH conditions
• Reasonable manufacturing tolerances

Multiparticulate release control

Pellet coating provides a platform for multiple release populations in a single capsule. The formulation may combine immediate-release and extended-release fractions to produce a controlled initial exposure followed by maintenance delivery. This architecture can support dose flexibility and may create formulation-specific intellectual property around coating composition, coating weight gain, pellet size distribution, and dissolution profiles.

Alcohol-dose-dumping control

Modified-release products should be evaluated in hydroalcoholic dissolution media when relevant to the product design. Hydrophilic matrices can behave differently in the presence of alcohol, and certain polymer systems may lose structural integrity. A formulation that preserves release control under alcohol challenge can reduce regulatory risk and support a differentiated product profile.

Food-effect management

Verapamil extended-release products should be evaluated under fed and fasted conditions. A robust excipient system can reduce sensitivity to meal composition, gastric motility, and changes in luminal fluid. Food-effect performance is commercially relevant because patients may take chronic cardiovascular therapy under variable daily conditions.

What formulations are protected by verapamil patents?

The original composition-of-matter and product exclusivity for verapamil hydrochloride expired decades ago. Current commercial protection is more likely to arise from formulation-specific patents, manufacturing know-how, trademarks, regulatory exclusivity, or contractual supply arrangements than from the active ingredient itself.

Potentially protectable formulation features include:

• Specific extended-release polymer combinations
• Multiparticulate pellet structures
• Coating compositions and pore-former systems
• Capsule-opening and sprinkle formulations
• Stable oral liquids or suspensions
• Injectable container and formulation systems
• Manufacturing processes that improve content uniformity or release consistency
• New combinations with other cardiovascular agents
• Selected method-of-use claims, where legally and clinically supportable

Patent protection must be assessed product by product. A formulation patent does not automatically block all verapamil generic products, and a generic applicant may challenge listed patents through a Paragraph IV certification if the relevant product is listed in the FDA Orange Book.[5]

What is the Orange Book status of verapamil hydrochloride?

Verapamil hydrochloride is a mature generic product with no active ingredient patent barrier comparable to a recently launched branded medicine. Orange Book analysis should distinguish among:

• Historical reference-listed drugs
• Currently marketed reference products
• Listed formulation or method-of-use patents
• Drug-specific exclusivity codes
• Therapeutically equivalent generic products

For most commercial diligence purposes, the primary barrier is not basic regulatory exclusivity. It is demonstrating bioequivalence for the selected dosage form and maintaining a reliable supply chain. Current Orange Book records should be reviewed for the exact reference product, dosage form, strength, and patent listings before filing or acquisition decisions.[5]

When does verapamil hydrochloride lose exclusivity?

Verapamil hydrochloride lost practical market exclusivity long before the current generic market developed. Immediate-release tablets, extended-release oral products, and injection are all subject to established generic competition in the United States.

Exclusivity category	Commercial position
Active-ingredient patent	Expired
Original product patent	Expired
U.S. chemical exclusivity	Expired
Biosimilar exclusivity	Not applicable
ANDA competition	Established
Current opportunity	Formulation, supply, geographic and service differentiation

The relevant commercial question is therefore not when verapamil loses exclusivity. It is whether a new manufacturer can obtain an acceptable return despite low unit pricing and existing generic competition.

Which companies are challenging verapamil hydrochloride products?

Verapamil hydrochloride is already challenged through the ordinary generic market rather than a concentrated, high-value Paragraph IV campaign. Generic competition has historically included large and mid-sized manufacturers, hospital suppliers, and regional pharmaceutical companies. The competitive set varies by dosage form and country.

The most important competitive distinctions are:

• Availability of all major strengths
• Consistency of extended-release dissolution
• Shortage performance
• Ability to supply hospitals and wholesalers
• Regulatory history
• Packaging flexibility
• Ability to support private-label or contract-manufacturing customers

A new entrant is more likely to compete through manufacturing reliability, a differentiated dosage form, or a regional supply agreement than through a conventional immediate-release tablet alone.

What generic entry risks exist for verapamil hydrochloride?

Generic entry risk is already high for standard immediate-release tablets and conventional extended-release products. A new product faces several risks:

1. Low pricing caused by multiple approved suppliers.
2. Limited switching incentives when existing products are therapeutically substitutable.
3. Bioequivalence complexity for modified-release formulations.
4. Product-specific dissolution differences that create regulatory questions.
5. Hospital and payer contracting pressure.
6. Active pharmaceutical ingredient price and supply volatility.
7. Recall exposure if release performance drifts.

The risk is lower for products with a distinct delivery benefit, such as a commercially viable sprinkle capsule, stable pediatric liquid, or shortage-resistant injectable presentation.

How strong is the patent estate for verapamil hydrochloride?

The patent estate is weak around the active ingredient and conventional dosage forms. It can be stronger around a specific formulation architecture, but the value depends on claim scope, freedom-to-operate analysis, prosecution history, and the ability to demonstrate non-obvious clinical or manufacturing advantages.

Patent layer	Relative strength
Verapamil hydrochloride molecule	Very weak; long expired
Conventional immediate-release tablet	Weak
Generic extended-release matrix	Weak to moderate
Specific multiparticulate coating system	Moderate if claims are narrow and technically supported
Pediatric liquid or stable suspension	Moderate, depending on formulation claims
Manufacturing process	Moderate where process parameters produce measurable product advantages
New combination or indication	Potentially stronger, but clinically and legally dependent

Patent value is highest where the formulation delivers a measurable difference in dissolution, pharmacokinetics, administration, stability, or adherence and where those results support non-obviousness.

What licensing deals and commercial partnerships are available?

Verapamil is suitable for several partnership models:

• Contract manufacturing of tablets or capsules for regional distributors
• Private-label extended-release products
• Hospital supply contracts for injection
• Licensing of multiparticulate or sprinkle technology
• Co-development of pediatric or geriatric formulations
• Technology transfer for local production in emerging markets
• Dual-source supply agreements to reduce shortage exposure

A licensing strategy should focus on the formulation platform rather than the molecule. An owner of a general-purpose controlled-release technology may license the platform for verapamil and other cardiovascular drugs. A finished-product company may instead seek a territory-specific commercialization license with manufacturing rights and regulatory support.

What FDA regulatory pathways support new verapamil formulations?

ANDA pathway

An ANDA is the standard route for a generic product that matches an approved reference product in active ingredient, dosage form, strength, route, labeling elements and performance requirements. Immediate-release tablets are generally the most straightforward opportunity. Extended-release products require more extensive comparative dissolution and pharmacokinetic work.[6]

505(b)(2) pathway

A 505(b)(2) application may be relevant where the proposed product differs materially from an approved product, such as:

• A novel oral liquid
• A new extended-release delivery system
• A different route or presentation
• A product with administration instructions not present in the reference label
• A formulation designed for a specific patient population

The pathway does not remove the need to address safety, efficacy, product quality, and patent certifications. It can, however, support a differentiated formulation when a simple ANDA is not appropriate.[7]

FDA guidance and product-specific expectations

The development program should follow FDA requirements for modified-release products, bioequivalence, dissolution, stability, and drug-device or container-closure considerations where relevant. The exact requirements depend on dosage form and reference product.[6,8]

What manufacturing and IP barriers affect commercial entry?

The main technical barriers are not synthesis of verapamil hydrochloride. They are dosage-form control and commercial execution.

Manufacturing barriers

• Uniform drug layering on pellets
• Consistent polymer coating thickness
• Control of agglomeration and fines
• Reproducible tablet hardness
• Scale-up of dissolution performance
• Moisture control during granulation and storage
• Sterile filling and particulate control for injection
• Container-closure compatibility
• Reliable supply of pharmaceutical-grade polymers

Intellectual-property barriers

• Existing extended-release claims
• Coating-process claims
• Capsule and sprinkle claims
• Stabilized oral-liquid claims
• Combination-product or method-of-use claims
• Know-how that is not publicly disclosed in patents

A freedom-to-operate review should cover U.S., European, Japanese, Chinese, Indian and target-market patent families. Patent risk can differ substantially by jurisdiction because older formulation patents may have expired in one market but remain enforceable in another through term adjustments, supplementary protection mechanisms, or national filing differences.

What are the strongest commercial opportunities for verapamil hydrochloride?

1. Extended-release supply recovery

A manufacturer with reliable capacity can capture share where incumbent suppliers experience shortages, allocation, or inconsistent wholesaler service. This opportunity is operational rather than patent-driven.

2. Sprinkle-compatible capsules

A capsule that can be opened and administered on soft food may address swallowing difficulty among older patients. The product must preserve release performance after administration and carry clear instructions.

3. Pediatric and geriatric oral liquid

A stable, accurately dosed liquid or suspension could address patients who cannot swallow tablets. Taste masking, dose uniformity, microbial control, sedimentation, redispersibility, and in-use stability determine commercial viability.

4. Hospital injectable supply

Injection can support a focused hospital business where supply continuity, packaging options, and dependable quality are more important than consumer branding. The product requires a validated sterile manufacturing network and strong quality systems.

5. Regional and emerging-market expansion

Countries with fragmented generic supply, limited extended-release availability, or high import dependence may offer better margins than the most competitive U.S. tablet market. Regulatory registration, local pharmacopoeial requirements, tender access, and local manufacturing rules are central to the business case.

6. Combination products

Fixed-dose combinations with other cardiovascular medicines may offer a differentiated commercial position, but they require clinical, pharmacokinetic, labeling, and regulatory analysis. Combination development also raises additional patent and freedom-to-operate issues.

How does verapamil compare with competing calcium-channel blockers?

Verapamil competes with diltiazem and dihydropyridine calcium-channel blockers such as amlodipine and nifedipine. The formulation opportunity differs by therapeutic profile.

Product class	Main formulation advantage	Commercial implication
Verapamil	Rate control and extended-release delivery	Opportunity in controlled release and dose administration
Diltiazem	Multiple modified-release architectures	Greater formulation competition but broader platform precedent
Amlodipine	Simple, stable once-daily oral dosing	Lower formulation complexity and lower differentiation potential
Nifedipine	Immediate- and modified-release systems	Strong competition in release-control technologies

Verapamil’s clinical effects on cardiac conduction make exposure control particularly important. A technically robust extended-release product can therefore have greater value than a standard immediate-release tablet, provided the product is priced and reimbursed competitively.

Key Takeaways

• Verapamil hydrochloride has no meaningful active-ingredient exclusivity remaining in the United States.
• Conventional immediate-release tablets are heavily commoditized.
• Extended-release tablets and multiparticulate capsules offer the clearest formulation-led opportunities.
• Hypromellose, ethylcellulose, polyethylene oxide, binders, disintegrants, lubricants and coating systems should be selected against dissolution and scale-up targets.
• Sprinkle-compatible capsules and stable oral liquids can address swallowing and dosing needs.
• Injectable verapamil offers hospital-supply potential but requires significant sterile-manufacturing capability.
• Biosimilar risk is irrelevant because verapamil hydrochloride is a small-molecule drug.
• Patent value is concentrated in formulation architecture, manufacturing processes and differentiated dosage forms.
• Commercial success depends more on supply reliability, regulatory execution and market access than on molecule-level patent rights.
• U.S. Orange Book, patent and litigation records should be assessed for the exact reference product and dosage form before investment or filing decisions.

Frequently Asked Questions

Can verapamil hydrochloride be formulated as a pediatric liquid?

Yes. A pediatric liquid or suspension could target patients unable to swallow tablets, but development must address taste, chemical stability, dose uniformity, microbial control, redispersibility and in-use stability. A differentiated liquid may be more suitable for a 505(b)(2) strategy than a conventional ANDA.

Which excipient is best for extended-release verapamil?

No single excipient is universally optimal. Hypromellose is a common starting point for hydrophilic matrix systems, while ethylcellulose, polyethylene oxide and methacrylate polymers can support alternative release architectures. Performance depends on polymer grade, concentration, tablet geometry and process conditions.

Is verapamil hydrochloride suitable for a 505(b)(2) application?

It may be suitable when the proposed product introduces a clinically meaningful formulation or delivery difference, such as a novel oral liquid, modified-release system or administration method. A conventional generic tablet generally fits the ANDA pathway more directly.

Are verapamil extended-release products vulnerable to dose dumping?

They can be if the formulation is sensitive to alcohol, agitation, food conditions, polymer variability or manufacturing changes. Hydroalcoholic dissolution, fed and fasted studies, and scale-up robustness are important parts of development.

Does verapamil hydrochloride have biosimilar competition?

No. Biosimilars apply to biological products. Verapamil hydrochloride is a chemically synthesized small-molecule drug and competes through generic-drug pathways.

References

1. U.S. Food and Drug Administration. (2024). Calan tablets: Verapamil hydrochloride prescribing information.

2. U.S. Food and Drug Administration. (2024). Calan SR: Verapamil hydrochloride extended-release tablets prescribing information.

3. U.S. Food and Drug Administration. (2024). Verelan: Verapamil hydrochloride extended-release capsules prescribing information.

4. U.S. Food and Drug Administration. (2024). Verapamil hydrochloride injection prescribing information.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.

6. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: General considerations.

7. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2).

8. U.S. Food and Drug Administration. (2015). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.